Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denufosol in post-cataract extraction macular edema
NCT00135655Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of denufosol tetrasodium in cystoid macular edema (CME) (3 arms), sponsored by Merck & Co. Primary endpoints: Safety, Tolerability and 2 more. Planned start Aug 2005; status: withdrawn.
02
Drugs
denufosol tetrasodium
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on NCT00135655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135655.